GASSER RODOLFO,HERNANDEZ MARIA-CLEMENCIA,THOMAS ANDREW
申请号：
NZ60859211
公开号：
NZ608592A
申请日:
2011.11.01
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed is the use of a GABA A a5 negative allosteric modulator of formula I or II for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions caused by neurodevelopmental defects which result in excessive GABAergic inhibition in the cortex and hippocampus. For example, the use of (1,1-dioxo-1,6-thiomorpholin-4-yl)-{ 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl} -methanone for the treatment, prevention and/or delay of progression of CNS conditions related to excessive GABAergic inhibition in the cortex and hippocampus, wherein said CNS condition is selected from cognitive defects in Down Syndrome, in autism, in neurofibromatosis type I, or after stroke.
